| Autor: |
Abrahim, Abduelmula, Brian D, Rankin, Ronald, Vender, Jensen, Yeung, Alim R, Devani, Vimal H, Prajapati |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Skin therapy letter. 27(3) |
| ISSN: |
1201-5989 |
| Popis: |
A novel topical corticosteroid, halobetasol propionate (HP) 0.01% lotion (Bryhali™), has recently been introduced for the treatment of plaque psoriasis and corticosteroid-responsive dermatoses in adults. Once daily application of HP 0.01% lotion is indicated for use up to 8 weeks. Treatment success for plaque psoriasis in the pivotal phase 3 clinical trials (defined as an Investigator Global Assessment [IGA] of clear/almost clear [IGA 0/1] with ≥2-grade improvement from baseline) occurred in over one-third of patients by week 8. Treatment-emergent adverse events were typically mild-to-moderate in intensity and usually limited to the application site(s). No treatment-related cases of skin atrophy have been reported from the studies. Counselling should be considered to optimize treatment outcomes. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
